Island Pharmaceuticals Signs CRADA to Advance Galidesivir Toward Animal Rule Approval
Island Pharmaceuticals Ltd (ASX: ILA) has formalised a three-year Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation. The partnership is focused on progressing Galidesivir under the US Food and Drug Administration’s Animal Rule pathway for the treatment of Marburg Virus Disease (MVD).
Through the agreement, the parties will collaborate on the design and execution of non-human primate studies required to support a potential New Drug Application for MVD. USAMRIID has previously contributed to Galidesivir’s development, including preclinical and primate research demonstrating antiviral activity against Ebola and Marburg viruses. The CRADA framework provides scope to broaden the collaboration if necessary, strengthening Island’s engagement within the US biodefence ecosystem and accelerating regulatory advancement for Galidesivir.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Island Pharmaceuticals Signs CRADA to Advance Galidesivir Toward Animal Rule Approval
Island Pharmaceuticals Ltd (ASX: ILA) has formalised a three-year Cooperative Research and Development Agreement with the US Army Medical Research Institute of Infectious Diseases and The Geneva Foundation. The partnership is focused on progressing Galidesivir under the US Food and Drug Administration’s Animal Rule pathway for the treatment of Marburg Virus Disease (MVD).
Through the agreement, the parties will collaborate on the design and execution of non-human primate studies required to support a potential New Drug Application for MVD. USAMRIID has previously contributed to Galidesivir’s development, including preclinical and primate research demonstrating antiviral activity against Ebola and Marburg viruses. The CRADA framework provides scope to broaden the collaboration if necessary, strengthening Island’s engagement within the US biodefence ecosystem and accelerating regulatory advancement for Galidesivir.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au